Four Corners Exposes Peptide Clinic Oversight Gaps
ABC investigation reveals longevity clinics exploiting telehealth prescribing loopholes to supply unapproved peptides, with lab tests finding contaminated products.
A national ABC Four Corners investigation has exposed how Australian longevity and wellness clinics are exploiting gaps in health regulation to prescribe unapproved peptides via telehealth consultations, prompting both the TGA and AHPRA to publicly confirm active enforcement responses.
What Four Corners found
The investigation, broadcast on 20 July 2026 and reported by ABC News, identified approximately 100 longevity operators that have opened across Australia. These clinics offer services including peptide prescriptions, NAD+ infusions, red light therapy, and cryotherapy.
ABC health reporter Rachel Carbonell booked a telehealth peptide consultation to test how easy it was to obtain a prescription. After submitting blood tests and a health summary at a cost of roughly $400, she received a telephone consultation in which a Queensland-based doctor prescribed a “stack” of four unapproved peptides. The treatment proposal, which had only a first name and no doctor’s signature, offered a four-to-six-week supply at a cost of $1,181.
The clinic’s compliance position, as reported by ABC News, was that its website did not advertise specific prescriptions and that booking a consultation did not guarantee medicine would be prescribed. The clinic has since removed and renamed that particular service offering.
Lab testing reveals product quality risks
Four Corners sent three samples of black-market peptides to a Melbourne laboratory for analysis. The testing, reported by ABC News, found that peptide concentrations varied widely, with one sample containing none of the advertised compound.
Analytical chemist Grace Hamann told the program the lab also found heavy metals in some samples, including significant amounts of potentially toxic free copper. “Generally, it’s there as a marketing gimmick to make the peptide in the vial appear blue,” she said.
TGA and AHPRA respond
The TGA’s chief medical adviser Professor Robyn Langham told ABC News that the majority of unapproved peptide supply was occurring via the black market, which the TGA is attempting to crack down on. Professor Langham pointed to the existing regulatory framework that allows doctors to prescribe unapproved products for compelling clinical needs, but noted the framework was not designed for routine access.
AHPRA chief executive Justin Untersteiner told the program the regulator was “concerned that some practitioners may be seeking to exploit the latest health trends by putting profits ahead of patients.” He confirmed AHPRA had open notifications regarding prescribing and supply of peptides and was acting proactively, “not just responding to complaints.”
The regulatory responsibility for peptide prescribing sits across two bodies. The TGA regulates therapeutic goods and strictly forbids advertising prescription or unapproved products. AHPRA and its national boards oversee the doctors and pharmacists who prescribe and dispense them.
Endocrinologist flags cancer risks
St Vincent’s Hospital endocrinologist Professor Katherine Samaras, who reviewed the treatment plan provided to the ABC reporter, described it as a legal document written to protect the prescribing company rather than to inform or treat the patient. She warned that the recommended one-month follow-up blood test was a red flag, noting that growth hormone stimulating peptides take three months to reach peak levels.
Professor Samaras identified cancer promotion as the most significant risk associated with the prescribed peptides, stating they act on cancer pathways. She also flagged risks including fluid retention, osteoarthritis, inflammation, and increased diabetes risk.
What to watch
The Four Corners investigation represents the most prominent national media coverage of the unregulated peptide market to date. The confirmed AHPRA investigations into peptide prescribing practices will be significant to monitor. The gap between TGA product regulation and AHPRA practitioner oversight remains the structural vulnerability that longevity clinics are operating within.
For researchers and procurement professionals, the lab testing findings reinforce the importance of Certificate of Analysis verification and sourcing from suppliers with documented quality controls.
Sources
- ABC News, “Telehealth peptide prescriptions expose longevity industry stretching the rules,” 20 July 2026: abc.net.au
- ABC Four Corners, “The Race to Reverse Aging,” broadcast 20 July 2026
For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.